CTLA4 and neoplasm: This approach has been exploited for the development of the bispecific antibody MEDI5752 enabling PD1 blockade and the preferential neutralization of CTLA4 on tumor-infiltrated PD1+ antigen-experienced T-cells, compared to PD1- T-cells [34].